Skip to main content
Premium Trial:

Request an Annual Quote

Despite Revenue, Stock Declines, Ciphergen s ProteinChip Business May Rebound

This article has been updated from an earlier version to include share price and details.

NEW YORK, Nov. 2 (GenomeWeb News) - Shares in Ciphergen Biosystems came to within 3 cents of their 52-week low in late-afternoon trade today after the company reported a 30-percent decline in third-quarter revenue and a nearly doubled net loss.

The stock was down 6.95 percent, or $.26, at $3.48 as investors fretted that the company's flagship ProteinChip mass spectrometry systems and BioSepra process chromatography products were losing strength in the marketplace.

 

But a research report released by Pacific Growth Equities today was optimistic, saying that Ciphergen's core business "appears to be strengthening" with 27 ProteinChip placements in the third quarter. Ciphergen said the placements included 19 of the company's newly released Series 4000 ProteinChip system.

 

The decline in share price also comes four days after Ciphergen said it will sell its BioSepra business to Pall for $32 million.

 

Pacific Growth said the BioSepra sale would infuse Ciphergen with "much needed cash" and give it an additional 12 months of "breathing room" and "leverage" to close diagnostic partnerships.

 

Revenues for the three months ended Sept. 30 totaled $11 million, down from $16 million during the same period last year, Ciphergen reported on Monday after the market closes.

 

R&D expenses declined to $4.7 million from $5.4 million during the year-ago quarter.

 

Ciphergen's loss for the quarter widened to $9.5 million, or $.33 per share, almost twice as much as last year's loss of $5.2 million, or $.18 per share, during the third quarter.

 

As of Sept. 30, Ciphergen had $19 million in cash, cash equivalents, and investments in securities.

The Scan

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.

Survey Sees Genetic Literacy on the Rise, Though Further Education Needed

Survey participants appear to have higher genetic familiarity, knowledge, and skills compared to 2013, though 'room for improvement' remains, an AJHG paper finds.

Study Reveals Molecular, Clinical Features in Colorectal Cancer Cases Involving Multiple Primary Tumors

Researchers compare mismatch repair, microsatellite instability, and tumor mutation burden patterns in synchronous multiple- or single primary colorectal cancers.

FarGen Phase One Sequences Exomes of Nearly 500 From Faroe Islands

The analysis in the European Journal of Human Genetics finds few rare variants and limited geographic structure among Faroese individuals.